A Developmental Roadmap Toward Abdominal Adhesions Prevention Technologies Authors: Reid R. Christensen, Kyla E. Wright, James K. Ives, Caroline E. Minnick, Queena Chen, Mark D. Girgis, Cliff Ko, Melinda Maggard Gibbons, Tara A. Russell, Tess C. Huy, Aron Bercz, J. Joshua Smith, Angela Bailey, Richard P.G. ten Broek, Rudy Leon de Wilde, Joel Zindel, Jessica C. Cardenas, Steven Mutsaers, David Wiseman, Emily A. Meany, Eric A. Appel, Deshka S. Foster, Daniel J. Delitto, Michael T. Longaker, Yuval Rinkevich, Steven R. Bauer, Samuel P. Carmichael Published: 2025 ABSTRACT Abdominal adhesions are a globally disruptive problem to patients and healthcare systems, with limited preventative strategies. Multiple discovery prophylactics have been evaluated previously for adhesions prevention with inadequate transfer to patient care. Clinical translation is fundamentally restricted by the ability of a discovery prophylactic to simultaneously navigate 3 key components of adhesions formation throughout the entire abdomen: the innate immune system, the coagulation system, and the local peritoneal cell populations. Furthermore, challenging handling characteristics and product restrictions have decreased the utilization of clinically available prophylactics by surgeons. The success of future adhesions prevention strategies must also be anchored in clinically valid animal modeling with attention towards future regulatory approval. The purpose of the present roadmap article is to provide a state-of-the-art review of adhesions pathophysiology, hydrogel development, animal modeling, and regulatory science, from which a framework for future developmental strategies may be outlined. INTRODUCTION Abdominal adhesions are pathologic scar tissue networks that develop between abdominal organs and the peritoneal lining after 90% of operations, conferring a lifelong risk of multiple major morbidities, including small bowel obstruction (SBO), female infertility, chronic pain, re-operative complications, and prolonged operative times.1,2 Operation for SBO carries a 7.2% risk of death, and health care costs associated with surgical division of abdominal scar tissue amount to billions of dollars per year in the USA, with an average of 7.8 days of hospital length of stay.1,3 While clinically available and investigational barrier films, pharmacological agents, and gels placed into the abdomen following operation have demonstrated incremental reductions in the degree of adhesions, none have led to a clinically meaningful impact upon the major adhesion-related complications.4 Thus, there is an urgent unmet need for the development of reliable adhesion prophylactic strategies.5 This review summarizes current knowledge concerning the 3 key components of adhesions formation: the innate immune system, coagulation system, and local peritoneal cell populations, illustrating the complex interplay between these systems.6 Recognized gaps in understanding exist between these systems, resulting in the thromboinflammatory and profibrotic environment of the postsurgical abdomen. Major questions remain regarding the optimal molecular targets and pathways for adhesions mitigation. Furthermore, animal modeling of abdominal adhesions remains nonstandardized and technically challenging, creating threats to external validity and therapeutic translation.7 This review will discuss these considerations while suggesting a framework toward the development of effective surgical adhesions prophylactics. THE INNATE IMMUNE SYSTEM IN ADHESION FORMATION The innate immune system within the abdomen is comprised of multiple cellular and acellular elements that perform constant surveillance of the serosal space during homeostasis. These elements coordinate inflammatory responses following specific types of disturbances, such as infection or tissue injury. One major, evolutionarily conserved cellular element of such immunity is the embryonically derived, self-renewing, tissue-resident macrophage—also known as the large peritoneal GATA6+ pericardial cavity macrophage (GPCM)—which is characterized by the transcription factor GATA6. GPCM surveil the abdominal cavity by convective recirculation within the fluidic peritoneal environment. Clearly, the GPCM depends on the serosal niche and requires specific signals such as colony-stimulating factor 1 and all-trans retinoic acid from the surrounding peritoneal mesothelial cells (PMCs)8,9 (Fig. 1). Following minor peritoneal disruptions, GPCM rapidly responds to the site of injury, aggregating in a platelet-like fashion to form an immediate wound covering.10 Aggregates also include the polymerization of coagulation factors and the recruitment of other immune cells, such as B-cells, monocytes, and mast cells, which are then coated by a layer of PMC to complete the healing process without residual scarring.11 The life cycle of a peritoneal macrophage before and after tissue injury. Created in BioRender.com. For significant tissue injury, such as open abdominal surgery or major microbial contamination/infection, the peritoneal repair system becomes dysregulated.12 Importantly, GPCM form super-aggregates upon injured tissues and become depleted. Referred to as the macrophage disappearance reaction (MDR), GPCMs are no longer identifiable in the peritoneal lavage.11,13 Importantly, the MDR is associated with augmentation of peritoneal fluid inflammatory cytokines and an influx of multiple cell types, including eosinophils, neutrophils, and GATA6−, monocyte-derived, small peritoneal macrophages from circulation.11,13 As such, the MDR indicates a threshold above which tissue injury exceeds a certain degree of severity, leading to subsequent inflammation, loss of scar-free repair, and need for GPCM repopulation.9,10 While certain factors have been identified to facilitate differentiation and repopulation of GPCM in the peritoneal cavity (ie, IL-4, retinoic acid, MSLN, Muc16, IRF4; Fig. 1), the effect of GPCM replenishment on adhesion formation remains unclear.11,14,15 The role of GPCM in adhesion formation is controversial, and GPCM depletion has been described both as pro- and antiadhesive in experimental surgical injury models.10,14,16 Despite these likely model- and context-dependent effects, there is a clear consensus that GPCMs are overall essential to the healing process within the abdomen.8,11 Previously, 2 prototypical macrophage phenotypes were used to describe macrophage activation states. While this heuristic has been less popular in more recent publications, it remains a useful framework for future studies on the role of macrophages in adhesion formation. M1-like macrophages, generally described as proinflammatory, aggregate to the site of injury and secrete IL-1α, IL-1β, TNF-α, IL-6, and NOS.17 By contrast, M2-like macrophages were considered a putatively anti-inflammatory late-stage subpopulation that promotes tissue repair.18 Abdominal adhesion formation has been shown as the result, in part, of oxidative stress via cytokines from M1-like macrophages.12 Increasing class switching from M1-like to M2-like macrophages and preventing the release of macrophage proinflammatory cytokines has resulted in abdominal adhesion reduction.12 Evaluations of several preclinical therapies (Supplemental Table S1, https://links.lww.com/AOSO/A558) measure populations of M1-like and M2-like macrophages as markers of immunomodulatory success at the site of tissue injury. Importantly, the concept of M1-like and M2-like macrophages has been largely derived from in vitro studies and can only partially be reconciled with the spectrum seen in macrophages isolated in vivo. In addition, with the rise of single-cell RNA-sequencing, the nomenclature of macrophage polarization states is currently undergoing a major revisional phase.17,19 Another innate immune cell population implicated in adhesion pathogenesis is neutrophils, specifically via the formation of neutrophil extracellular traps (NETs).20 NETs are formed by neutrophils undergoing 2 separate pathways: (1) lytic NETosis, whereby neutrophils decondense their nucleus, release cytoplasmic contents, and rupture, and (2) vital NETosis, where neutrophils remain functionally active within the complex and capable of responding to infection.20,21 This pathway is important to the human innate immune response by ensnaring and killing invading pathogens. However, NETosis has also been implicated in autoimmune disease and aseptic conditions, including abdominal adhesion formation.20 The degradation of NETs is primarily mediated by DNases, though physiologic levels of DNases alone are insufficient to clear NETs.22 DNase I dismantles NETs to facilitate clearance by macrophages, highlighting the importance of functional macrophage populations at the site of injury.13,22 One study by Tsai et al13 found that the transient depletion of neutrophils and increased recruitment of macrophages to the site of injury led to decreased adhesion formation in a mouse model. Neutrophils have recently been shown to function in adhesion formation by a process involving the transfer of extracellular matrix (ECM) in the large cavity organs.23 The process of ECM transferal is mediated by integrin alpha M (CD11b) and integrin beta 2 (CD18) dimerization on neutrophil cell surfaces, followed by physical binding of integrins to tissue/organ ECM and ‘piggybacking’ into specific sites of injury for ECM accretion and scar formation.23 The complex orchestrations of different immune cell types within the peritoneum following injury are vital to our understanding of adhesiogenesis and subsequent successful prophylactic development. Macrophage populations are a prominent cell type in the abdominal cavity and take a leading role, along with neutrophils, in the promotion and reconciliation of the abdominal healing process. The complex continuum between cavitary resident and monocyte-derived macrophages has yet to be resolved by a comprehensive characterization of subpopulations. Questions remain as to the most favorable subpopulation to promote in the setting of adhesion prophylaxis.18 State of the Art Prophylactic Considerations: The Innate Immune System Novel prophylactics shown to impact the innate immune system tend to fall into 3 categories: agents for intraperitoneal application, pharmaceuticals, and regenerative medicine approaches influencing the immune response during adhesion formation. Medicated and nonmedicated physical barriers have been tested in preclinical studies and found to decrease macrophage expression and aggregation, decrease macrophage inflammatory markers, and/or promote reprogramming of macrophages. Pharmaceuticals have been found to either decrease macrophage aggregation or promote reprogramming of macrophages. Stem cell fat grafting, pretreated stem cell therapy, and small molecule derivatives of PMC have all been shown to modulate the innate immune response and decrease adhesion formation. A majority of these studies have not yet progressed beyond preclinical trials, consisting of experiments conducted in rodent models and in vitro studies (Supplementary Table S1, https://links.lww.com/AOSO/A558). THE COAGULATION RESPONSE IN ADHESION FORMATION Damage to the peritoneum inseparably triggers co-activation of the innate immune response and the coagulation response (Fig. 2). The culminating event of the coagulation system is the generation of the proinflammatory protease thrombin (Factor IIa), leading to peritoneal fibrin polymerization from fibrinogen, and the creation of the persistent fibrin gel matrix.6 Under nonpathological conditions, the coagulation cascade is counterbalanced by fibrinolysis, a process in which plasminogen is converted to plasmin by tissue plasminogen activator (t-PA) or urokinase plasminogen activator (u-PA). Once active, plasmin mediates the degradation of fibrin bands into fibrin degradation products, restoring homeostasis.24–26 Essential initiating components of the coagulation system (ie, cell surface factor V, extracellular vesicles containing phospholipids, cell surface tissue factor) and the fibrinolytic system are produced by macrophages and PMC, reinforcing that innate immune activation precedes activation of the coagulation system in peritoneal healing.24,27 Within the vasculature, cytokines activate coagulation effector cells such as neutrophils, platelets, monocytes, and endothelial cells to convert from an anticoagulant to a procoagulant state. The coagulation cascade, fibrinolysis, and its mediators in the formation of adhesions. Local tissue hypoxic conditions following injury favor the maintenance of the persistent fibrin gel matrix, which ultimately undergoes reorganization and collagen deposition to form abdominal adhesions.6 Classically, this antifibrinolytic phenomenon is primarily attributed to a surge in plasminogen activator inhibitor-1 (PAI-1), the central inhibitor of t-PA and u-PA released from vascular endothelial cells, PMC, macrophages, platelets, and fibroblasts.24 While multiple preclinical and clinical investigations have attempted to establish a clear relationship between the expression and activity of t-PA and PAI-1 in the formation of postsurgical adhesions, this has remained an area of ongoing challenge due to heterogeneity in study design and sampling.24 While the coagulation system is primed to be pro- rather than anticoagulant, both procoagulant and antifibrinolytic systems appear to augment in the postsurgical abdomen, leading to an increase in fibrin formation.24 Additional mediators playing a role in the regulation of the fibrinolytic system include α2-antiplasmin and matrix metalloproteinases (MMP).28 Alpha2-antiplasmin (α2-AP), a product of the liver, inhibits the activity of plasmin and is itself inhibited by MMP-3, promoting degradation of the fibrin gel matrix.28 In this way, MMP-3 is a central regulator of the fibrinolytic system and can additionally inactivate PAI-1 and α2-AP, leading to increased plasmin. In return, plasmin can activate additional MMP subtypes to facilitate remodeling of the ECM.29,30 As fibrin serves as a scaffold for immune cell activation and chemoattraction, this may serve as a mechanism by which inflammation is resolved in the abdomen. Taken together, evidence from preclinical evaluations has pointed to suppression of fibrinolysis as a key step in adhesion formation. Anticoagulants and fibrinolytic agents were among the earliest strategies studied for adhesion prevention and have included citrate, heparin, aspirin, ancrod, thromboxane A2 receptor blockade, t-PA, u-PA, and streptokinase.24,31 Though some preclinical studies demonstrated efficacy in animals, results were inconsistent and not without several pitfalls. In particular, there were significant concerns for an increased risk of hemorrhagic complications and impaired wound healing.32–34 Subsequent work explored different modes of delivery (eg, aerosolized intraperitoneal heparin, combining intraperitoneal heparin with barriers) to reduce systemic heparin exposure and mitigate the risk of complications.35 Inhibitors of vascular endothelial growth factor (VEGF) such as bevacizumab have been recently studied in adhesion prevention, as they are shown to increase tissue t-PA and decrease tissue PAI-1 levels, alternating the balance of t-PA/PAI-1 in favor of fibrinolysis.36 Several animal studies have investigated the antiadhesive effects of anti-VEGF agents, each demonstrating a significant decrease in postoperative adhesion scores.36–38 That said, the use of anti-VEGF agents in treating abdominal malignancies has previously been linked to side effects and complications, including impaired wound and anastomotic healing.39,40 Nonetheless, only 2 clinical investigations have been conducted on human subjects with no clinical effect on adhesions prevention.24,41 State of the Art Prophylactic Considerations: The Coagulation System Ultimately, a successful prophylactic solution will likely need to effectively impact the thromboinflammatory environment of the peritoneum. Potential directions of investigation have included the development of inhibitors against intrinsic cascade factors, platelet-specific factors, and damage-associated molecular protein inhibitors. Synthetic heparin and heparan sulfates have allowed for molecular fine-tuning to include both anticoagulant and anti-inflammatory functions. The resulting molecule (ie, Dekaparin) has similar anticoagulation properties to fondaparinux but can also bind and sequester damage-associated molecular proteins out of circulation. Preclinical studies have shown that this molecule can significantly reduce fibrin deposition and leukocyte infiltration into end organs.42 Manipulation of the coagulation response illustrates a delicate balance between inhibiting adhesions while preserving coagulation and healing processes throughout the perioperative period. As a result, attempts at modifying fibrinolysis have led to very few human studies, with relatively limited progress towards a safe and effective fibrinolytic strategy for adhesion prevention, despite decades of research.18 THE PERITONEAL CELL RESPONSE IN ADHESION FORMATION The peritoneum is composed of a single layer of specialized epithelial (mesothelial) cells (PMC) anchored to a basal membrane, composed of fibroblasts, adipocytes, immune cells, blood vessels, nerves, and ECM. The peritoneum lines the serous cavities of the body (the abdomen, pericardium, and pleura), along with most vital organs.43 Within the peritoneum, mesothelial cells play important roles in maintaining peritoneal homeostasis. This includes the provision of an antifriction glycocalyx [ie, epithelial glycocalyx (EpGL)] to facilitate free movement of abdominal organs. PMC also regulates peritoneal fluid and cellular exchange with the blood circulation, initiating and regulating inflammatory and fibrotic tissue repair processes via the secretion of a wide range of cytokines, growth factors, and ECM molecules.44 Studies have shown that PMC, in conjunction with fibroblasts derived from the underlying basal membrane, are primary participants in adhesion formation.45,46 A key component of this is the process of mesothelial-to-mesenchymal transition (MMT), in which mesothelial cells adopt mesenchymal phenotypes and behaviors.47,48 Collagen-secreting myofibroblasts are required for adhesion fibrosis. While the published data are controversial, whether these myofibroblasts arise through activation of preexisting fibroblasts or from MMT-transformed PMC, both sources are likely to be important.49,50 On the surface of mesothelial cells lies a thin film of EpGL, composed of ECM molecules such as hyaluronan, syndecan, heparan sulfate, chondroitin sulfate, and mucin. This glycocalyx acts as a lubricant for the peritoneal viscera and protects the mesothelial surface from abrasions and adhesion induction.51 During surgical operations, the EpGL is the first layer to be traumatized (Fig. 3) by direct tissue injury and desiccation, allowing mesothelial cell damage, driving transcriptional changes reflective of the MMT phenotype, and activating cells within the underlying basement membrane occurring within the first 6 to 8 hours after injury.47,48 The initiation of such gene expression changes within the mesothelial cells leads to the downregulation of genes characteristic of epithelial-type cells, such as E-cadherin, and the upregulation of genes characteristic of mesenchymal-origin cells. Furthermore, production of ECM molecules, like type I collagen, fibronectin, and elastin, can be induced from mesothelial cell lines in vitro, suggesting that these cells contribute to fibrosis.52,53 Furthermore, injury to the mesothelial cell monolayer results in activation of underlying fibroblasts and immune cells. This cascade of local cellular activation and associated genomic changes among peritoneal cell types results in early transcriptional regulator activation of factors HIF-1α and c-JUN.12,50 These signaling pathways offer therapeutic opportunities for adhesions mitigation. Taken together, these cellular activities and gene expression changes subserve the global process of wound healing within the abdomen and the formation of pathologic adhesions. The peritoneal cellular response in abdominal adhesion formation. Created in BioRender.com. Following injury to the peritoneum, activated PMCs, fibroblasts, and local immune cells stimulate systemic responses from the innate immune and coagulation systems through the production of proinflammatory and profibrotic cytokines. A fibrin matrix forms and is infiltrated by mobile mesothelial cells and local peritoneal fibroblasts that secrete ECM components. With the deposition of ECM proteins from peritoneal fibroblasts and MMT-induced mesothelial cells, the fibrotic adhesion is established beyond primordial inflammation. Recent data show that visceral peritoneal surfaces contribute more to these tissues than do parietal surfaces, supporting the clinical finding that laparoscopy reduces but does not eliminate complications due to adhesions.50,54 These pathologic connections between organ surfaces continue to mature with the ingrowth of blood vessels and nerve tissue, impairing the free movement of organs in the abdomen.24,26 State of the Art Prophylactic Considerations: The Peritoneum Recent improvements in understanding of the peritoneum’s role in adhesion formation have guided prophylaxis research towards targeting early cellular events within peritoneal cell populations.55 Within the last decade, a variety of preclinical evaluations (Supplementary Table S2, https://links.lww.com/AOSO/A558) have focused on biochemical and targeted therapeutics impacting peritoneal mesothelial and fibroblast cells during fibrosis. Of these, several involved repurposing medications already on-market, such as metformin and rapamycin. Biomarkers evaluated included proinflammatory cytokines, such as TNF-α and IL-6, profibrotic growth factors, such as transforming growth factor beta and associated proteins, collagens, and the SMAD family of signal transduction proteins (Supplementary Table S2, https://links.lww.com/AOSO/A558). Experiments with small molecules included gene expression assays for transcription factors implicated early in fibrosis (eg, HIF-1α and c-JUN).12,50 Treatment approaches included oral, intraperitoneal application, intragastric administration, subcutaneous osmotic pumps, and subcutaneous injections, with some of the noted studies requiring daily intraperitoneal local injections to achieve successful reduction in adhesion severity. While these routes of administration may be technically possible in an experimental model, implementation in the clinical setting may be more challenging. Ideally, a one-time intraperitoneal administration of an effective, sustained-release agent at the conclusion of an operation would deliver therapy directly to the cells responsible for adhesions formation without requiring pre- or post-operative patient or caregiver compliance. HYDROGELS FOR PERITONEAL APPLICATIONS Since their discovery in the 1960s, synthetic hydrogels have proven to be a highly versatile class of materials with a wide array of biomedical uses and engineering potential.56 With respect to adhesion prevention, hydrogels represent a cavitary iteration of barrier technologies, acting as prophylactic physical barriers with added potential to enable precise and prolonged drug delivery or local environmental modulation. Hydrogels have been extensively investigated for antiadhesion applications, detailed in several reviews along with other biomaterial modalities.56–60 Broadly, hydrogels can be defined as three-dimensional water-swollen polymer networks. The high-water content of hydrogels, upward of 99 wt% for some, makes them particularly compatible with water-rich environments, like the human body, and bioactive compounds, like protein therapeutics. The landscape of hydrogel use in the clinic is rapidly evolving, with over 100 Food and Drug Administration (FDA)-approved hydrogel products and 210 active clinical trials to date for applications ranging from cosmetic surgery and contact lenses to wound healing, cancer treatment, and many others.61 For adhesion prevention, a multitude of hydrogels are in preclinical or clinical development, with a few approved for use outside of the United States, including Hyalobarrier (Nordic Pharma, Paris, France), Oxiplex (Nordic, Tonsberg, Norway), 4DryField PH (PlantTecMedical, Luneburg, Germany), Hyaregen (Bioregen, Changzhou, China), and Guardix-SG (Hanmi Pharmaceutical Co. Ltd., Seoul, Korea).5,55 Within the United States, Adept (Ethicon, Somerville, NJ), Interceed (Ethicon, Somerville, NJ), and Seprafilm (Baxter, Deerfield, IL) remain the only FDA-approved products.62 Hydrogels can be categorized in several ways, including by their crosslinking chemistries, whether static or dynamic.63 Static hydrogels are typically formed with inflexible covalent crosslinks and maintain stable mechanical properties over time and in response to different stimuli. Dynamic hydrogels, on the other hand, are formed with transient crosslinks that can break and reform, rearranging over time to produce dynamic materials with a broad range of viscoelastic properties, including self-healing or nondestructive deformation. Dynamic materials can be engineered to be injectable or sprayable, making them easy to apply in minimally invasive or open surgical procedures and allowing quick, full coverage of a surgical field. Some static hydrogels can also be applied with spraying, particularly if the covalent crosslinking chemistries are biocompatible and can be invoked after the polymer solution is applied to a surgical site, as is done with SprayShield. Application ease and coverage are particularly relevant in preventing adhesions in the large peritoneal cavity, where timely and complete coverage of the highly folded surfaces minimizes infection risk and limits adhesions. Hydrogels can further be classified based on the source of their component polymers: synthetic, such as polyethylene glycol, polyvinyl alcohol, or polylactic acid, or natural, such as cellulose, chitosan, or hyaluronic acid and derivatives.58,59 Synthetic polymers offer a high degree of control over polymer composition and properties, yielding reproducible hydrogels, while natural polymers can vary batch-to-batch due to derivation from biological sources. Natural polymers are often considered more biocompatible than synthetic, and some contain signaling domains with anti-inflammatory properties, like the CD44 binding motifs in hyaluronic acid.56 On the other hand, synthetic polymers often have longer residence times in the body, which can be beneficial when used as an antiadhesion barrier, and can be bioinert or engineered with antifouling properties to resist protein or cellular depositions in vivo.60 State of the Art Prophylactic Considerations: Hydrogels In using hydrogels to prevent peritoneal adhesions, there are several key material considerations. The hydrogel should be (1) biocompatible and not induce inflammation or negatively impact wound healing, (2) easy to apply with full coverage of the surgical area and surrounding tissues in minimal time to limit infection risk, and (3) resorbable, yet remain at the application site minimally for the duration of the acute inflammatory and adhesion-initiation stage.64 Lastly is the material price when considering mass production for clinical applications. While hydrogels with natural or synthetic polymers can meet these criteria, the specific polymers and crosslinking chemistries, as well as bulk hydrogel mechanical properties like stiffness and viscoelasticity (storage and loss moduli), will contribute to application ease, degradation timescale, tissue adhesion or dislodging, and biocompatibility. Beyond their prophylactic capacity as barriers, hydrogels can modulate the local tissue environment, especially through their capacity as drug delivery vehicles. In the past few decades, a deeper understanding of the underlying biology driving adhesion formation has resulted in several categories of therapeutics or active factors that could limit adhesion progression and serve as payloads to be delivered by hydrogel technology. These include anti-inflammatory agents like nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants like heparin, fibrinolytics like t-PA, transforming growth factor beta inhibitors, or gene regulators like JUN-inhibitor T-5224.50,57–60,64,65 In this way, hydrogel technologies have the potential to prevent abdominal adhesions through their own intrinsic barrier properties and act as delivery instruments for therapeutics directed at the cells responsible for adhesions formation. Furthermore, distributive, degradation, and adsorptive properties of gels would allow therapeutics to be cycled through the peritoneal cavity while limiting off-target side effects of systemic drug administration. Ultimately, very few hydrogels are approved for clinical use, and none in the United States, highlighting a need for more extensive and translational investigations into their utility as adhesions prophylactics. CONSIDERATIONS OF ANIMAL MODELING Animal models are foundational for understanding disease states or evaluating therapies, with numerous advantages over human testing. However, as there is no such thing as a perfect model for all scenarios, limitations are critical to identify when selecting the appropriate model organism. While a highly valid animal model may contribute to the translational success of a discovery therapeutic, the lack of external validity may negatively impact treatment effect sizes, standardization, and impair clinical translation. As with other disease processes, the most appropriate animal model for abdominal adhesions research should be contextualized in the outcome of interest.66 A useful lens for looking at animal models is the trifecta of fidelity, homology, and discrimination7 (Fig. 4). Fidelity highlights how superficial resemblance does not necessarily dictate the usefulness of an animal model, and studies in more distantly related animals may have limited direct applicability to human patients.18,67 Homology describes how similar the disease proceeds between animals and humans. Discrimination refers to how an animal model responds to a given treatment or exposure. While the animal model may respond favorably toward a pharmaceutical intervention, the same therapy may induce life-threatening reactions in human subjects.68 Key considerations of the external validity of induced experimental animal models. Created with BioRender.com. Reproduced from Carmichael et al 2024.7 Mice are commonly used to model human diseases and test therapies due to their quick reproductive cycle, ease of maintenance, and the degree of similarity to human biology. However, mice have different molecular and immunological processes from humans and demonstrate different biochemical responses for the same diseases.67 Fortunately, there are multiple points of overlap in the fibrotic pathways contributing to abdominal adhesions between mice and humans, including markers of the MMT and fibroblast activation pathways, such as COMP, TIMP1, COL1A1, and COL3A1.50 Furthermore, mouse and human fibroblasts may both be identified by expression of JUN, PDGFRA, aSMA and FSP1.50 The congruency of these pathways in both humans and mice makes them commonly used organisms in abdominal adhesions research. Generating animal models producing SBO has been challenging and under-targeted.69 Commonly, degrees and quantifications of fibrosis have been used as surrogate endpoints and extrapolated to human clinical disease states. Adhesions models that create scar tissue to a limited area and generalize findings to an SBO are at risk for an overestimation of treatment effect. Models employing tissue injury through access to the entire abdomen are more likely valid to the clinical disease process.7,70 Another limitation of animal research is the absence of standardized metrics in evaluating animals for disease and intervention outcomes.33,71 Nearly all animal studies in a recent systematic review and meta-analysis of preclinical evaluations of adhesion barriers employed a different scoring system.72 The authors suggest further that the incidence of adhesions is the most clinically relevant outcome, as only their absence will truly preclude the complications of SBO. Imprecise ordinal scales with varying degrees of subjectivity further distract from this endpoint, as they incorporate multiple features that may not be related or equally predictive of the clinical outcome.73 Furthermore, traditionally employed scoring systems focus on a single site of injury rather than comprehensively assessing the entire abdomen.18 Prevention of these issues through the use of objective scoring criteria is a critical component to precise outcomes measurement and a key factor for clinical translation. Researchers must conduct their animal research with the same best-practice rigor as experiments involving human subjects: blinding their observers when possible, applying randomization with interventions, clearly selecting investigative endpoints with suitable power and control groups, and determining inclusion/exclusion criteria before beginning data collection. Translational research would also benefit from more universal and standardized metrics for evaluating animals and their disease states, to improve validity for comparing different animal studies. Animal models are not without their limitations, but at this stage, further mechanistic studies on adhesions are necessary and useful for helping future patients. REGULATORY SCIENCE FOR DISCOVERY TECHNOLOGIES Preclinical research to address the challenge of abdominal adhesion treatment includes the promise of developing innovative approaches using the capabilities of regenerative medicine. Clinical use of such novel approaches would be conducted with US FDA oversight during the entire therapeutic development from investigational clinical trials up to and after licensure and marketing. If preclinical researchers are familiar with the appropriate regulatory landscape, the process of bench-to-bedside translation can be substantially improved, regulatory and scientific pitfalls can be avoided, and patients will benefit in an expedited fashion. The FDA defines regenerative medicine therapy as “a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations.74 Regenerative medicine therapies are regulated as biologics under the Public Health Service Act section 351. “351” products follow a regulatory pathway from Investigational New Drug (IND) in the developmental period to Biologics License Application and licensure for marketing. There are many opportunities for interaction with the FDA in the preclinical period, including INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs) and pre-IND meetings. INTERACT is a meeting where one can obtain FDA feedback early in product development before any regulatory timelines are applied. An INTERACT meeting request can be submitted when a sponsor has identified the investigational product to be evaluated in a clinical study and conducted some preliminary preclinical proof-of-concept studies with the intended investigational product, but has not yet designed and conducted definitive toxicology studies. This meeting type is specifically designed to save sponsors time and money by avoiding inappropriate preclinical studies, with a focus on animal toxicology studies.75 A second mechanism for early FDA input before any formal regulatory submission is the pre-IND meeting. Pre-IND meetings provide feedback on a sponsor’s product development program, especially if a sponsor’s questions are not fully answered by guidance documents and other publicly available resources. The primary purpose of this meeting is to obtain feedback on the design of preclinical and initial clinical studies and product manufacturing and quality controls needed to initiate human studies. The goals of different phases of product development change in terms of the rigor of manufacturing process control, product characterization, validation of the analytical procedures used for product testing and release, and demonstration that the manufacturing is well-controlled. In early phase trials, especially phases 1 and 2, safety is the primary goal, and preliminary evidence of effectiveness and proper product dosing is determined. To receive marketing authorization, sponsors must conduct rigorous, statistically significant analytical and clinical testing showing that the product demonstrates: (1) sterility; (2) purity; (3) potency; (4) identity; (5) stability; (6) safety; and (7) efficacy.76 Reaching these goals can be challenging since there are many complex components of cell-based regenerative medicine products, including cells, biomaterials, growth factors, and novel procedures for manufacturing, such as bioprinting. The FDA does not prescribe the analytical methods to meet the regulatory requirements for potency, purity, and identity. Due to the complexity of cell-based regenerative medicine products, the development of measurements and characteristics that predict safety and clinical effectiveness remains some of the most challenging scientific issues facing product developers and preclinical researchers. As an approach to better define mesenchymal stromal cell attributes more predictive of potency, the FDA’s mesenchymal stromal cell consortium chose a strategy of developing quantitative bioassays followed by attempts to correlate product characteristics with the bioassay outcomes. Image-based morphological measurements provided positive correlations with in vitro bioassay results and illustrate that this general strategy may be amenable to the identification of the molecular pathways that are associated with specific levels of biological activity.77 It is hoped this approach will help cell therapy developers to find meaningful potency assays that predict clinical effectiveness. Improvement of regenerative medicine product characterization can be a time-consuming, finicky, costly, and iterative process, but the goal of such regulatory science is to find product release tests (especially purity, identity, and potency) that have a molecular basis, are robust and rapid, that are good manufacturing practice friendly, and economical. A high-level understanding of the regulatory approach for regenerative medicine pathways will be advantageous for those doing discovery research, as in this context, with novel adhesions prophylactic products. CONCLUSIONS The formation of postsurgical adhesions is a complex phenomenon, involving the contributions of multiple homeostatic operating systems within the abdomen. At such a crossroads of biological sophistication, a solution to the problem of adhesions must either leverage or satisfy key inputs from each system without further provocation. Hydrogel prophylactics represent a versatile platform of barrier technologies and can serve as tunable materials to deliver biologically active payloads. Adhesions prevention strategies in the discovery phase must thoughtfully consider the limitations of animal modeling and the future practical obstacles of operating room implementation. Early engagement with the FDA, while considering the 7 key points of regulatory science, is essential to successful clinical translation. While the most effective adhesions prophylactic has yet to be produced, this review may serve as the best guidance for its development (Table 1). TABLE 1.Recommendations for Development of a Successful Abdominal Adhesion Prophylactic Best Practice Recommendations for Adhesion Prophylactic Development Target key pathophysiologic mechanismsAn adhesion prophylactic should address the 3 essential components of adhesions formation: the innate immune response, coagulation response, and peritoneal mesothelial cell response following surgical injury. Particularly, signaling pathways at points of overlap early in the development of abdominal adhesions should be prioritized.Ensure sustained intraperitoneal activitySuccessful products should provide a sustainable effect throughout the entire peritoneal cavity, durable, but not disruptive, through the various stages of the healing process.Design for ease of application in the operating roomProducts must be easy to apply throughout the abdomen without changing the surgical approach. Operating room staff should be able to quickly prepare the product within the sterile field before abdominal closure.Evaluate in representative adhesion modelsNovel prophylactics should be studied in a model organism with fidelity, homology, and discrimination of treatment effect. Adhesions burden must be objectively quantified throughout the entire abdomen using a standardized adhesion scoring system.Anticipate and prepare for regulatory barriersA successful product will be Good Manufacturing Practices friendly, and researchers are encouraged to engage early and often with federal regulating bodies to ensure an expedited transition from bench to bedside. Recommendations for Development of a Successful Abdominal Adhesion Prophylactic ACKNOWLEDGEMENTS The authorship wishes to gratefully acknowledge the Carlino family, whose generous support facilitated presentation and discussion of this work at the Surgical Adhesions Improvement Project Summit in Washington, DC, September 19–20, 2024. This effort was part of the ongoing Surgical Adhesions Improvement Project, an initiative of the American College of Surgeons www.facs.org/quality-programs/research-programs/surgical-adhesions-improvement-project/. The Surgical Adhesions Improvement Project is led by the Surgical Consortium on Adhesions Research (SCAR) Advisory Group. SURGICAL CONSORTIUM ON ADHESIONS RESEARCH (SCAR) ADVISORY GROUP Reid R. Christensen, Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, NC; Mark D. Girgis, Cliff Ko, Melinda Maggard Gibbons, Tara A. Russell, and Tess C. Huy, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; Aron Bercz and J. Joshua Smith, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Bailey, American College of Surgeons, Chicago, IL; Samuel P. Carmichael, Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, NC, and Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC. Supplementary Material